Navigation Links
Genmab's HuMax-EGFr Shows Broad Potential in Cancer Treatment

COPENHAGEN, June 3, 2007 - Genmab A/S (CSE: GEN) announced today pre-clinical data illustrating its fully human HuMax-EGFr™ (zalutumumab) antibody may have broad potential to treat cancers that over-express several types of EGFr (epidermal growth factor receptor).

Recently, mutations which appear to alter the signaling ability of EGFr have been identified in tumors from lung cancer patients. Such mutations may be a critical factor in the potential success of EGFr-directed treatments in lung cancer.

In a novel cancer cell laboratory model, HuMax-EGFr effectively inhibited the growth of tumor cells that express both mutated or normal EGF receptors. This inhibition occurred through different mechanisms of action including direct inhibition of cancer cell growth and an immune cell-mediated killing activity known as antibody dependent cell-mediated cytotoxicity (ADCC).

Genmab scientists also used the model to test the effects of tyrosine kinase inhibitors (TKI) such as the marketed products Iressa and Tarceva on EGFr-expressing tumor cells. Tumor cells expressing various mutated EGFr varied strongly in their sensitivity to TKI therapy, whereas no differences in efficacy where observed for HuMax-EGFr.

"This pre-clinical data indicates that HuMax-EGFr may have more potential in the treatment of some types of cancer, such as lung cancer, than tyrosine kinase inhibitors," said Lisa N. Drakeman, Ph.D., Chief of Genmab.

These data will be presented today in a poster session at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, USA.


'"/>




Page: 1

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 Global Surgical Drainage ... are tubes used to remove excess liquid and air. ... pus, urine, bile or lymph. Surgical drains are used ... such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery ... post-surgery to prevent accumulation of fluid e.g. blood or ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... April 27, 2017 , ... Last night, Christine Collins of ... Year for her extraordinary compassion and lifelong dedication to serve others. Since 1997, ... for the prestigious award each year – identifying a CAREGiver who has exemplified ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Offering the ... with an oil many times purer and more potent than the market has seen ... of Gstaad, Switzerland, as well as a patented chromatography process for extraction, to produce ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, Inc., an innovative ... has completed a round of funding to accelerate its growth strategies. The $3.5 ... Capital is a growth equity firm focused on investments in healthcare and technology ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... the ATA 2017 President’s Awards recipients, comprised of organizations and individuals who ... , The ATA 2017 President’s Awards recognize individuals and organizations on ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, ... been honored by Enterprising Women magazine as one of its 2017 Enterprising Women ... business owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively ...
Breaking Medicine News(10 mins):